Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0
|
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Huang, D. [3 ]
Sun, Y. [4 ]
Wu, L. [5 ]
Zhou, C. [6 ]
Zhou, J. [7 ]
Guo, Y. [8 ]
Chen, L. [9 ]
Shao, J. [9 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China
[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Selpercatinib; RET fusion-positive NSCLC; China; ORR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.01
引用
收藏
页码：S888 / S889
页数：2
相关论文
共 50 条
  • [31] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Sun, Decong
    Yang, Xuejiao
    Yuan, Fang
    Ju, Yanfang
    Wang, Lijie
    Wang, Jinliang
    Zhao, Wei
    Zhang, Dong
    Li, Lin
    Xu, Xiaoyun
    Ma, Junxun
    Hu, Yi
    Zhang, Xiaotao
    SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
  • [32] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Ming Gao
    Xia Zhang
    Huan Yan
    Decong Sun
    Xuejiao Yang
    Fang Yuan
    Yanfang Ju
    Lijie Wang
    Jinliang Wang
    Wei Zhao
    Dong Zhang
    Lin Li
    Xiaoyun Xu
    Junxun Ma
    Yi Hu
    Xiaotao Zhang
    Supportive Care in Cancer, 2023, 31
  • [33] Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion plus non-small cell lung cancer
    Zhou, Q.
    Wu, Y-L.
    Zhao, J.
    Chang, J.
    Wang, H.
    Fan, Y.
    Wang, K.
    Wu, G.
    Nian, W.
    Gong, Y.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Zheng, X.
    Qin, M.
    Duan, X.
    Shen, Z.
    Yao, S.
    Yang, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1593 - S1593
  • [34] Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas
    Belluomini, Lorenzo
    Avancini, Alice
    Pasqualin, Luca
    Insolda, Jessica
    Sposito, Marco
    Menis, Jessica
    Tregnago, Daniela
    Trestini, Ilaria
    Ferrara, Miriam Grazia
    Bria, Emilio
    Milella, Michele
    Pilotto, Sara
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 785 - 794
  • [35] An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)
    Nguyen, Vanessa Quang
    Geirnaert, Marc
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (02) : 450 - 456
  • [36] Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion-positive non-small cell lung cancer: a case report
    Scattolin, Daniela
    Scagliori, Elena
    Scapinello, Antonio
    Fantin, Alberto
    Guarneri, Valentina
    Pasello, Giulia
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [37] Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
    Illini, Oliver
    Hochmair, Maximilian Johannes
    Fabikan, Hannah
    Weinlinger, Christoph
    Tufman, Amanda
    Swalduz, Aurelie
    Lamberg, Kristina
    Hashemi, Sayed M. S.
    Huemer, Florian
    Vikstrom, Anders
    Wermke, Martin
    Absenger, Gudrun
    Addeo, Alfredo
    Banerji, Shantanu
    Calles, Antonio
    Clarke, Stephen
    Di Maio, Massimo
    Durand, Alice
    Duruisseaux, Michael
    Itchins, Malinda
    Kaaranien, Okko-Sakari
    Krenn, Florian
    Laack, Eckart
    de Langen, Adrianus Johannes
    Mohorcic, Katja
    Pall, Georg
    Passaro, Antonio
    Prager, Gerald
    Rittmeyer, Achim
    Rothenstein, Jeffrey
    Schumacher, Michael
    Woell, Ewald
    Valipour, Arschang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [38] Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers.
    Subbiah, Vivek
    Konda, Bhavana
    Bauer, Todd
    McCoach, Caroline
    Falchook, Gerald
    Takeda, Masayuki
    Patel, Jyoti
    Weiss, Jared
    Peled, Nir
    Bazhenova, Lyudmila
    Soldatenkova, Victoria
    French, Pearl
    Drove, Nora
    Gautschi, Oliver
    Drilon, Alexander
    CANCER RESEARCH, 2021, 81 (13)
  • [39] Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
    Stinchcombe, Thomas E.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1655 - 1657
  • [40] Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer
    Bhandari, Naleen Raj
    Hess, Lisa M.
    Han, Yimei
    Zhu, Yajun E.
    Sireci, Anthony N.
    IMMUNOTHERAPY, 2021, 13 (11) : 893 - 904
12345